1Watanabe T,Akieda Y,Suzuki T,et al.Clinical trials of a new quinolone, sparfloxacin, in skin and skin structure infections[].Drugs.1993
2Matsuda S,Japanese Collaborative Study Group of Sparfloxacin in Gynecology.Clinical experience with sparfloxacin in the treatment of gynaecological infection[].Drugs.1993
3Tillotson GS.Quinolones: structure-activity relationships and future predictions[].Journal of Medical Microbiology.1996
4Portier H,May T,Proust A,et al.Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia[].Journal of Antimicrobial Chemotherapy.1996
5Ritz M,Lode H,Fassbender M,et al.Multiple dose pharmacokinetics of sparfloxacin and its influence on fecal flora[].Antimicrobial Agents and Chemotherapy.1994
6Montay G.Pharmacokinetics of sparfloxacin in heal thy volunteers and patients: a review[].Journal of Antimicrobial Chemotherapy.1996
7Tack KJ,Smith JA.The safety profile of ofloxacin·47·[].The American Journal of Medicine.1989
8Allegra L,Konuetzko N,Leophonte P,et al.Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised,parallel , multicentre study[].Journal of Antimicrobial Chemotherapy.1996
9Karren L G,Harriet M,Anthony Markham.Sparfloxacin a review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections[].Drugs.1997
10Franz -Josef Schmitz,Basia Hofmann,Birgit Hansen,et al.Relationship between ciprofloxacin, ofloxacin,levofloxacin, sparfloxacin and moxifloxacin (BAY 128039 ) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus[].Journal of Antimicrobial Chemotherapy.1998
